Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, investigator-blinded, cross over, prospective, single center study of
subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone
dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone
dipropionate 0.064%) Topical Suspension will each be applied topically once daily.
The primary objective is to assess the patient preference for Taclonex® (calcipotriene 0.005%
and betamethasone dipropionate 0.064%) Ointment compared to Taclonex Scalp® (calcipotriene
0.005% and betamethasone dipropionate 0.064%) Topical Suspension in the treatment of plaque
psoriasis.